Overview

A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Diffe

Status:
Completed

Trial end date:
2015-06-27

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the overall survival of patients receiving E7080 + Best Supportive Care (BSC) with those receiving placebo + Best Supportive Care.

Phase:

Phase 2

Details

Lead Sponsor:

Eisai Inc.

Collaborator:

Quintiles, Inc.

Treatments:

Lenvatinib